{"organizations": [], "uuid": "6419a2afeb98eab5a147f1460529468a1553ada7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-teva-pharm-comments-from-conferenc/brief-teva-pharm-comments-from-conference-call-post-q1-results-idUSJ7N1NL00F", "country": "US", "domain_rank": 408, "title": "BRIEF-Teva Pharm comments from conference call post-Q1 results", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-03T21:09:00.000+03:00", "replies_count": 0, "uuid": "6419a2afeb98eab5a147f1460529468a1553ada7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-teva-pharm-comments-from-conferenc/brief-teva-pharm-comments-from-conference-call-post-q1-results-idUSJ7N1NL00F", "ord_in_thread": 0, "title": "BRIEF-Teva Pharm comments from conference call post-Q1 results", "locations": [], "entities": {"persons": [{"name": "schultz", "sentiment": "negative"}, {"name": "tova cohen", "sentiment": "none"}, {"name": "steven scheer", "sentiment": "none"}], "locations": [{"name": "u.s", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "teva", "sentiment": "negative"}, {"name": "teva pharmaceutical industries ltd", "sentiment": "negative"}, {"name": "teva pharm", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3, 2018 / 1:09 PM / Updated 7 minutes ago BRIEF-Teva Pharm comments from conference call post-Q1 results Reuters Staff 1 Min Read\nMay 3 (Reuters) - Teva Pharmaceutical Industries Ltd :\n* TEVA PHARM CEO SCHULTZ: STILL EXPECT TO SELL $4 BILLION WORTH OF GENERIC DRUGS IN U.S. IN 2018\n* TEVA PHARM CEO SCHULTZ: MIGRAINE DRUG LIKELY TO BE APPROVED FOR QUARTERLY DOSAGE\n* TEVA PHARM CEO SCHULTZ: NO PLANS TO ISSUE NEW EQUITY, NO PLANS FOR M&A ACTIVITY\n* TEVA PHARM: DEVELOPING PEN DEVICE FOR MIGRAINE DRUG BUT NO SPECIFIC DATE FOR LAUNCH\n* TEVA PHARM CFO: EXPECTS TO PAY DOWN ANOTHER $1.3-$1.5 BILLION OF DEBT IN 2018\n* TEVA PHARM: NO EXPECTATION FOR ANOTHER 40 MG GENERIC VERSION OF COPAXONE IN 2018 Further company coverage: (Reporting by Steven Scheer and Tova Cohen)", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-03T21:09:00.000+03:00", "crawled": "2018-05-03T16:18:49.027+03:00", "highlightTitle": ""}